Skip to search formSkip to main contentSkip to account menu

marizomib

Known as: (1R,4R,5S)-4-(2-chloroethyl)-1-{(S)-[(1S)-cyclohex-2-en-1-yl]hydroxymethyl}-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, Salinosporamide A, Salinosporin A 
A naturally-occurring salinosporamide, isolated from the marine actinomycete Salinospora tropica, with potential antineoplastic activity. Marizomib… 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (2)

LactonesPyrroles
NCIt Antineoplastic Agent TerminologyPositive Regulation of ApoptosisProteasome Function InhibitionSignal Transduction Inhibition

Narrower (1)

NPI 0052

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Ligand Based-Pharmacophore Modeling and Extended Bi oactivity Prediction for Salinosporamide A, B and C from Marine Actino mycetes Salinispora tropica.
AIM AND OBJECTIVE Actinomycetes produce structurally unique secondary metabolites with pharmaceutically essential bioactivities… 
2016
2016
Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label…
Marizomib (MRZ) is a novel, irreversible, pan subunit proteasome inhibitor (PI) with preclinical evidence demonstrating in vitro… 
2016
2016
Marizomib for CNS-Multiple Myeloma
Marizomib, a natural marine product, is an irreversible proteasome inhibitor (PI) that has distinct advantages over the currently… 
2015
2015
Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and…
Introduction: MRZ is a novel, irreversible, proteasome inhibitor (PI) under clinical development for the treatment of relapsed… 
Review
2013
Review
2013
Proteasome inhibitors in acute leukemia
Proteasome inhibition has been recognized as a novel treatment modality in hematologic malignancies. Initially, the reversible… 
Review
2012
Review
2012
Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.
Although patients with B-cell non-Hodgkin's lymphoma (NHL) usually respond to initial conventional chemotherapy, they often… 
2011
2011
Elucidation of the α-keto-aldehyde binding mechanism: a lead structure motif for proteasome inhibition.
Lead role: The role of peptidyl alpha-keto aldehydes as proteasome inhibitors is well established, yet their molecular binding… 
2009
2009
Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition.
Many marketed drugs contain fluorine, reflecting its ability to modulate a variety of biological responses. The unique 20S… 
Highly Cited
2008
Highly Cited
2008
Total synthesis of salinosporamide A.
The total synthesis of salinosporamide A has been achieved through enzymatic desymmetrization, diastereoselective aldol reaction… 
Highly Cited
2005
Highly Cited
2005
New synthetic route for the enantioselective total synthesis of salinosporamide A and biologically active analogues.
[reaction: see text] A total synthesis of the salinosporamide analogue 3 is described that starts with the novel cyclization 4… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)